Y. Shintani et al., GS-164, A SMALL SYNTHETIC COMPOUND, STIMULATES TUBULIN POLYMERIZATIONBY A SIMILAR MECHANISM TO THAT OF TAXOL, Cancer chemotherapy and pharmacology, 40(6), 1997, pp. 513-520
Purpose: During our search for new microtubule effecters as anticancer
agents, we have found that a small synthetic molecule designated GS-1
64 interferes with the assembly of porcine microtubule proteins and ha
s cytotoxic activity against a wide range of human tumor cell lines. I
n this study, we investigated mode of action of the compound in compar
ison with Taxol and colcemid. Methods: To gain an insight into the mod
e of action of GS-164, we used an in vitro microtubule polymerization
assay and a flow-cytometric measurement technique. Microtubule organiz
ation and the level of tubulin polymerization in HeLa cells were also
examined by immunofluorescence microscopy and cytoskeletal protein ana
lyses, respectively. Results: GS-164 stimulated assembly of microtubul
e proteins in vitro in a concentration-dependent and a GTP-independent
manner. Furthermore, as with Taxol, the microtubule polymerization in
duced by GS-164 was antagonized by podophyllotoxin, a tubulin polymeri
zation inhibitor, and microtubules formed by GS-164 were resistant to
disassembly by calcium or low temperatures. GS-164 in the micromolar r
ange arrested the cell cycle of HeLa cells in the mitotic phase leadin
g to cell death. GS-164 also increased the amounts of cellular microtu
bules in HeLa cells, resulting in the formation of microtubule bundles
. Conclusion: These results indicate that GS-164 stimulates microtubul
e assembly by a similar mechanism to that of Taxol. A comparative conf
ormational analysis of GS-164 and Taxol suggested that the structure o
f the former mimics the minimum essential sites of Taxol required to e
xert the Taxol-like activities described above. Although the cytotoxic
ity of GS-164 against human tumor cells was 1000-fold lower than that
of Taxol and GS-164 was one-tenth as active as Taxol in vitro, these f
indings pave the way for synthesizing clinically useful anticancer age
nts using GS-164 as a lead compound.